Clinical trials: Endocrine Disease
Elevated Triglycerides, Diabetes
Change of Fructose to Fat in South Asians
The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).
- Conditions
- Elevated Triglycerides, Diabetes, Cardiovascular Disease, Dyslipidemia
- Trial name
- NCT01562782
- Testing
- Fructose + Glucose Beverage
- Where
- 2 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- The Rogosin Institute
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Primary Objective: To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin (HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not adequately controlled on insulin…
- Trial name
- GetGoal-Duo-2 (NCT01768559)
- Testing
- Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID
- Where
- 199 sites in United States, Canada and 16 more
- Volunteers
- 894 people
- Sponsor
- Sanofi
Diabetes Mellitus
Chronic Care Management/Patient Relationship Management Proof of Concept
This proof of concept study proposes to evaluate the feasibility of a communications-technology-based chronic care and patient relationship management program to improve diabetes self management among adult diabetic patients in…
- Trial name
- NCT01182480
- Testing
- Patient Relationship Management (PRM) Program
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Denver Health and Hospital Authority
Male Hypogonadism
Safety and Efficacy Trial of Testosterone Undecanoate
The purpose of the study is to determine if oral testosterone undecanoate is effective and safe in the treatment of low testosterone in men.
- Trial name
- NCT01765179
- Testing
- Oral testosterone undecanoate
- Where
- 27 sites in United States
- Volunteers
- 144 people
- Sponsor
- Clarus Therapeutics, Inc.
Hyperparathyroidism, Secondary
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
The purpose of this study is to characterize the safety and tolerability of single rising doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism.
- Trial name
- NCT01134562
- Testing
- Etelcalcetide
- Where
- 5 sites in United States, Australia
- Volunteers
- 28 people
- Sponsor
- KAI Pharmaceuticals
Type 1 Diabetes
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).
- Trial name
- TIDM (NCT00529191)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Philadelphia
Breast Neoplasms, Endocrine Breast Diseases
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
About a third of patients with breast cancer are usually treated by hormone pills called tamoxifen and aromatase inhibitors. Aromatase inhibitors are drugs that stop female hormone production.
- Conditions
- Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
- Trial name
- NCT01499160
- Testing
- letrozole, lapatinib, everolimus
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
Ovarian Cancer
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer.
- Trial name
- CORAIL (NCT02421588)
- Testing
- Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan
- Where
- 28 sites in United States
- Volunteers
- 442 people
- Sponsor
- PharmaMar
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Healthy
Controlled Randomized Study With Athena Base Plate Versus SenSura Base Plate on Perspiring Skin
Aim The aim of the Athena project is to develop an ostomy product that is softer and more flexible in order to improve the comfort for people with a stoma.
- Trial name
- NCT01245413
- Testing
- SenSura, Athena
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Type 1 Diabetes
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system.
- Trial name
- NCT00797823
- Testing
- Insulin, Asp(B28)-, Glucagon
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Legacy Health System
Type 2 Diabetes Mellitus
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a…
- Trial name
- NCT02738879
- Testing
- Sitagliptin, Metformin, Metformin XR
- Volunteers
- 746 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy
The aim of the project is to document the international routine practice in sensor usage in patients treated with sensor-augmented pump therapy and to assess which variables (e.g.
- Trial name
- NCT00790088
- Where
- 26 sites in Austria, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation…
- Trial name
- NCT00679042
- Testing
- Islets of Langerhans transplantation
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CellTrans Inc.
Diabetes
ADA Linagliptin in Long Term Care
This is a study to determine whether glycemic control, as measured by change in HbA1c and frequency of hypoglycemia, is different between treatment with linagliptin (Tradjenta®) and basal insulin in long term care residents(LTC)…
- Trial name
- NCT02061969
- Testing
- linagliptin, insulin glargine
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- Emory University
Ovarian Cancer, Breast Cancer
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic…
- Trial name
- SOLI (NCT04330040)
- Testing
- Olaparib
- Where
- 16 sites in India
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A
Glutathione is normally present at high (millimolar) levels in blood and plays an important role in the body's defense against oxidative stress, that is, against the damage caused to the body by reactive oxygen species produced…
- Trial name
- NCT00858897
- Testing
- Cysteine isotope infusion at normoglycemia vs hyperglycemia, Regular Insulin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Nemours Children's Clinic
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
Pancreatic Cancer
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
This trial will include 2 portions (phase 1 and phase 2). The first portion will be a Phase I, open label, dose escalation study to establish the maximum tolerated dose (MTD) of XB2001 as measured by Dose-Limiting Toxicity (DLT)…
- Trial name
- 1-BETTER (NCT04825288)
- Testing
- Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- XBiotech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.